Skip to main content

Hepion Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Apr 8, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 8, 2025

HEPA$0.11-13.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page hereto)

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, John Brancaccio, and each of them acting individually, as his attorney-in-fact, with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ JOHN BRANCACCIOInterim Chief Executive Officer/Chief Financial Officer, DirectorApril 8, 2025
John Brancaccio(Interim Principal Executive Officer and Financial Officer)
/s/ MICHAEL PURCELLDirectorApril 8, 2025
Michael Purcell
/s/ TIMOTHY BLOCKDirectorApril 8, 2025
Timothy Block
/s/KAOUTHAR LBIATIDirectorApril 8, 2025
Kaouthar Lbiati
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.